Is It Time to Screen the General Population for Type 1 Diabetes?

Area of Science:

• Immunology
• Endocrinology
• Public Health

Background:

• Type 1 diabetes (T1D) is a chronic autoimmune disease causing progressive destruction of pancreatic beta cells.
• T1D incidence has doubled in recent decades, increasing associated morbidity and mortality.
• Current T1D risk prediction relies on detecting islet autoantibodies (IAs) years before clinical onset, primarily in relatives or genetically predisposed individuals.

Purpose of the Study:

• To review the history and rationale for general population screening for T1D risk.
• To discuss the arguments for and against widespread T1D screening.
• To highlight the potential impact of advances in IA measurement on T1D prevention strategies.

Main Methods:

• Review of historical data on T1D screening initiatives.
• Analysis of current diagnostic capabilities for islet autoantibodies (IAs).
• Discussion of epidemiological trends in T1D incidence and prevalence.

Main Results:

• Islet autoantibodies (IAs) are reliable predictors of T1D, detectable years before diagnosis.
• Over 85% of new T1D cases lack a family history, suggesting limitations of targeted screening.
• Advances in IA measurement facilitate consideration of general population screening.

Conclusions:

• General population screening for T1D risk is becoming feasible due to predictable biomarkers.
• Weighing the benefits against the challenges of widespread screening is crucial.
• Future T1D management may involve early detection and intervention through population-level screening.